Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Antitumor immunity against bladder cancer induced by ex vivo expression of CD40 ligand gene using retrovirus vector

Cancer Gene Therapy volume 10, pages 833–839 (2003)Cite this article

Abstract

The interaction between CD40 ligand (CD40L) and CD40 on antigen-presenting cells is essential for the initiation of antigen-specific T-cell responses. In order to clarify whether the expression of CD40L in tumor cells might be useful as a systemic therapy against bladder cancer, we investigated the antitumor immunity induced by CD40L in the mouse bladder cancer cell line MBT2. MBT2 was transduced by the retroviral vector expressing CD40L (MBT2–CD40L). Mouse bone marrow-derived dendritic cells cocultured with MBT2–CD40L cells produced eight times more IL-12 than those cocultured with parental MBT2 cells. In animal studies, subcutaneously inoculated MBT2–CD40L cells were rejected promptly. The vaccination of MBT2–CD40L cells induced antitumor immunity against parental tumors at a distant site. However, the antitumor effect of MBT2–CD40L inoculation was insufficient against pre-existing tumors. In the vaccination model, antibody ablation studies revealed that CD4+ T cells were required for antitumor immunity, and tumor-specific cytotoxicity of sera was demonstrated. These data demonstrated that the antitumor immunity induced by CD40L was effective in the vaccination model and suggested that immunogene therapy using CD40L may be a new strategy of systemic therapy against bladder cancer.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4
Figure 5
Figure 6
Figure 7
Figure 8

Similar content being viewed by others

References

  1. Eto M, Harada M, Tamada K, et al. Antitumor activity of interleukin-12 against murine bladder cancer. J Urol. 2000;163:1549–1552.

    Article  CAS  Google Scholar 

  2. Grossmann ME, Brown MP, Brenner MK . Antitumor responses induced by transgenic expression of CD40 ligand. Hum Gene Ther. 1997;8:1935–1943.

    Article  CAS  Google Scholar 

  3. Nakajima A, Kodama T, Morimoto S, et al. Antitumor effect of CD40 Ligand: elicitation of local and systemic antitumor responses by IL-12 and B7. J Immunol. 1998; 161:1901–1907.

    CAS  Google Scholar 

  4. Kikuchi T, Crystal RG . Anti-tumor immunity induced by in vivo adenovirus vector-mediated expression of CD40 ligand in tumor cells. Hum Gene Ther. 1999;10:1375–1387.

    Article  CAS  Google Scholar 

  5. Durie FH, Foy TM, Masters SR, et al. The role of CD40 in the regulation of humoral and cell-mediated immunity. Immunol Today. 1994;15:406–411.

    Article  CAS  Google Scholar 

  6. Grewal IS, Flavell RA . CD40 and CD154 in cell-mediated immunity. Annu Rev Immunol. 1998;16:111–135.

    Article  CAS  Google Scholar 

  7. Jenkins MK . The ups and downs of T cell costimulation. Immunity. 1994;1:443–446.

    Article  CAS  Google Scholar 

  8. Caux C, Massacrier C, Vanbervliet B, et al. Activation of human dendritic cells through CD40 cross-linking. J Exp Med. 1994;180:1263–1272.

    Article  CAS  Google Scholar 

  9. Cella M, Scheidegger D, Palmer-Lehmann K, et al. Ligation of CD40 on dendritic cells triggers production of high levels of interleukin-12 and enhances T cell stimulatory capacity: T-T help via APC activation. J Exp Med. 1996;184:747–752.

    Article  CAS  Google Scholar 

  10. Koch F, Stanzl U, Jennewein P, et al. High level IL-12 production by murine dendritic cells: upregulation via MHC class II and CD40 molecules and downregulation by IL-4 and IL-10. J Exp Med. 1996;184:741–746.

    Article  CAS  Google Scholar 

  11. Robbins PB, Yu XJ, Skelton DM, et al. Increased probability of expression from modified retroviral vectors in embryonal stem cells and embryonal carcinoma cells. J Virol. 1997;71:9466–1974.

    CAS  PubMed  PubMed Central  Google Scholar 

  12. Pear WS, Nolan GP, Scott ML, et al. Production of high-titer helper-free retroviruses by transient transfection. Proc Natl Acad Sci USA. 1993;90:8392–8396.

    Article  CAS  Google Scholar 

  13. Danos O, Mulligan RC . Safe and efficient generation of recombinant retroviruses with amphotropic and ecotropic host ranges. Proc Natl Acad Sci USA. 1988;85:6460–6464.

    Article  CAS  Google Scholar 

  14. Joki T, Kikuchi T, Akasaki Y et al. Induction of effective antitumor immunity in a mouse brain tumor model using B7-1 (CD80) and intercellular adhesive molecule 1 (ICAM-1; CD54) transfection and recombinant interleukin 12. Int J Cancer. 1999;82:714–720.

    Article  CAS  Google Scholar 

  15. Akasaki Y, Kikuchi T, Homma S, et al. Antitumor effect of immunizations with fusions of dendritic and glioma cells in a mouse brain tumor model. J Immunother. 2001;24:106–113.

    Article  CAS  Google Scholar 

  16. Kikuchi T, Akasaki Y, Joki T, et al. Antitumor activity of interleukin-18 on mouse glioma cells. J Immunother. 2000;23:184–189.

    Article  CAS  Google Scholar 

  17. Monach PA, Schreiber H, Rowley DA . CD4+ and B lymphocytes in transplantation immunity. Transplantation. 1993;55:1356–1361.

    Article  CAS  Google Scholar 

  18. Fujieda M, Oishi N, Kurashige T . Antibody to endothelial cells in Kawasaki disease lyse endothelial cells without cytokine pretreatment. Clin Exp Immunol. 1997;107:120–126.

    Article  CAS  Google Scholar 

  19. Loskog A, Bjorkland A, Brown MP, et al. Potent antitumor effects of CD154 transduced tumor cells in experimental bladder cancer. J Urol. 2001;166:1093–1097.

    Article  CAS  Google Scholar 

Download references

Acknowledgements

We thank Dr H Yagita for kindly providing mouse CD40L cDNA, Dr I Hara for MBT2, Dr DB Kohn for retroviral vector pMND-X-SN, Dr S Saito for hybridoma GK 1.5 and 56.6.73, Dr S Honma and Dr N Kuwashima for helpful advice, and Ms C Yoshimoto and Ms S Iizuka for excellent technical assistance. This study was supported in part by the Takeda Science Foundation.

Author information

Authors and Affiliations

  1. Department of Urology, The Jikei University School of Medicine, Tokyo, Japan

    Takahiro Kimura, Hiroshi Kiyota & Yukihiko Ohishi

  2. Department of Gene Therapy, Institute of DNA Medicine, The Jikei University School of Medicine, Tokyo, Japan

    Takahiro Kimura, Toya Ohashi, Tetsuro Kikuchi & Yoshikatsu Eto

Authors
  1. Takahiro Kimura
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Toya Ohashi
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Tetsuro Kikuchi
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Hiroshi Kiyota
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Yoshikatsu Eto
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Yukihiko Ohishi
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Takahiro Kimura.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Kimura, T., Ohashi, T., Kikuchi, T. et al. Antitumor immunity against bladder cancer induced by ex vivo expression of CD40 ligand gene using retrovirus vector. Cancer Gene Ther 10, 833–839 (2003). https://doi.org/10.1038/sj.cgt.7700627

Download citation

  • Received:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.cgt.7700627

Keywords

This article is cited by

Search

Advanced search

Quick links